SCHEMBL8224587

SCHEMBL8224587

CON(C)C(=O)C1c2ccc(Cl)cc2CCN1B(C)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.37
NOTUM Q6P988 2/20 0.37
MMP12 P39900 2/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP7 P09237 1/20 0.35
MMP9 P14780 1/20 0.35
MMP14 P50281 1/20 0.35
MMP15 P51511 1/20 0.35
MMP16 P51512 1/20 0.35
MMP26 Q9NRE1 1/20 0.35
GHSR Q92847 1/20 0.35
GRIN2C Q14957 2/20 0.34
FKBP1A P62942 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
CA14 Q9ULX7 1/20 0.34
SRD5A1 P18405 2/20 0.33
SRD5A2 P31213 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12216859 0.83 NOTUM (0.42) TRPV1NOTUMMMP12MMP1MMP2
SCHEMBL8224705 0.80 NOTUM (0.39) TRPV1NOTUMMMP12MMP1MMP2
SCHEMBL8417697 0.78 GHSR (0.51) TRPV1GHSR
SCHEMBL8222663 0.68 FNTA (0.36) TRPV1NOTUMCA1CA2CA9
SCHEMBL8276148 0.68 GHSR (0.51) TRPV1GHSR
SCHEMBL8222646 0.66 SLC6A15 (0.45) TRPV1NOTUMGHSRGRIN2C
SCHEMBL18084398 0.65 ACE (0.51)
SCHEMBL29048526 0.64 MEN1 (0.45)
SCHEMBL8225732 0.64 SLC6A15 (0.45) TRPV1GHSR
SCHEMBL8224318 0.63 GHSR (0.54) GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039467-B2 Compounds for the treatment of inflammatory disorders SCHERING CORPORATION (US) 2011-10-18 US disclosed
US-20100145048-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS SCHERING CORPORATION 2010-06-10 US disclosed
US-7652020-B2 novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction SCHERING CORPORATION (US) 2010-01-26 US disclosed
US-7638513-B2 Compounds for the treatment of inflammatory disorders SCHERING CORPORATION (US) 2009-12-29 US disclosed
US-20070167426-A1 Compounds for the treatment of inflammatory disorders and microbial diseases SCHERING CORPORATION 2007-07-19 US disclosed
US-20060178366-A1 Compounds for the treatment of inflammatory disorders SCHERING CORPORATION 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167426-A1 Compounds for the treatment of inflammatory disorders and microbial diseases MMP12, ADAMTS1, ADAM33 TRPV1 1257/4885NOTUM 1088/4885MMP12 1/4885
US-20060178366-A1 Compounds for the treatment of inflammatory disorders MMP12, ADAMTS1, TNF TRPV1 1158/4885NOTUM 1457/4885MMP12 1/4885
US-20100145048-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TNF, MMP12, MMP8 TRPV1 1191/4885NOTUM 793/4885MMP12 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.